MAVANCLAD Trademark

Trademark Overview

On Wednesday, January 18, 2017, a trademark application was filed for MAVANCLAD with the United States Patent and Trademark Office. The USPTO has given the MAVANCLAD trademark a serial number of 79207880. The federal status of this trademark filing is CANCELLED - SECTION 71 as of Friday, May 10, 2024. This trademark is owned by Merck KGaA. The MAVANCLAD trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical products, namely, pharmaceutical preparations for the treatment of inflammatory and immunological diseases and disorders
mavanclad

General Information

Serial Number79207880
Word MarkMAVANCLAD
Filing DateWednesday, January 18, 2017
Status709 - CANCELLED - SECTION 71
Status DateFriday, May 10, 2024
Registration Number5314424
Registration DateTuesday, October 24, 2017
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 8, 2017

Trademark Statements

Goods and ServicesPharmaceutical products, namely, pharmaceutical preparations for the treatment of inflammatory and immunological diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, May 10, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameMerck KGaA
Party Type30 - Original Registrant
Legal Entity Type31 - NOT AVAILABLE
AddressDE
Party NameMerck KGaA
Party Type20 - Owner at Publication
Legal Entity Type31 - NOT AVAILABLE
AddressDE
Party NameMerck KGaA
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressDE

Trademark Events

Event DateEvent Description
Tuesday, May 30, 2017APPLICATION FILING RECEIPT MAILED
Friday, June 9, 2017REFUSAL PROCESSED BY MPU
Thursday, May 18, 2017SN ASSIGNED FOR SECT 66A APPL FROM IB
Thursday, May 25, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, May 25, 2017ASSIGNED TO EXAMINER
Friday, May 26, 2017NON-FINAL ACTION WRITTEN
Saturday, May 27, 2017NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, July 19, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 8, 2017PUBLISHED FOR OPPOSITION
Tuesday, August 8, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 5, 2017TEAS POST PUBLICATION AMENDMENT RECEIVED
Friday, June 9, 2017NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, June 29, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, June 29, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, June 29, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, June 29, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, June 29, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, July 1, 2017REFUSAL PROCESSED BY IB
Wednesday, September 27, 2017CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Tuesday, October 24, 2017REGISTERED-PRINCIPAL REGISTER
Wednesday, January 24, 2018FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Friday, March 16, 2018FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, October 24, 2022COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, May 10, 2024CANCELLED SECTION 71
Monday, January 29, 2018FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, September 26, 2017ASSIGNED TO PETITION STAFF
Monday, January 29, 2018FINAL DISPOSITION PROCESSED

Related Keywords

mavanclad pharmaceutical immunological diseases disorders inflammatory treatment products namely preparations